Darunavir/cobicistat, sold under the brand names Prezcobix (US) and Rezolsta (EU), is a fixed-dose combination antiretroviral medication used to treat and prevent HIV/AIDS.[3] It contains darunavir and cobicistat.[3][5][6] Darunavir is an HIV protease inhibitor and cobicistat increases the effectiveness of darunavir by blocking its metabolism by the enzyme CYP3A.[6][3]

Darunavir/cobicistat was approved for use in the European Union in November 2014, and for use in the United States in January 2015.[4][7][8][3][9]

References

  1. ^ "Cobicistat / darunavir (Prezcobix) Use During Pregnancy". Drugs.com. 25 June 2019. Retrieved 19 February 2020.
  2. ^ "Drug and medical device highlights 2018: Helping you maintain and improve your health". Health Canada. 14 October 2020. Retrieved 17 April 2024.
  3. ^ a b c d e "Prezcobix- darunavir ethanolate and cobicistat tablet, film coated". DailyMed. 6 June 2019. Retrieved 20 February 2020.
  4. ^ a b "Rezolsta EPAR". European Medicines Agency (EMA). Retrieved 4 April 2020.
  5. ^ "Darunavir / Cobicistat". AIDSinfo. U.S. Department of Health and Human Services. Archived from the original on 3 March 2020. Retrieved 29 June 2018.
  6. ^ a b "Darunavir and Cobicistat (Professional Patient Advice)". Drugs.com. 16 September 2019. Retrieved 19 February 2020.
  7. ^ "Antiretroviral drugs used in the treatment of HIV infection". U.S. Food and Drug Administration (FDA). 12 April 2018. Retrieved 19 February 2020.
  8. ^ "Darunavir/Cobicistat (Prezcobix) Combo Pill Clears FDA". Medscape. 30 January 2015.
  9. ^ "Prezcobix (darunavir and cobicistat) Tablet". U.S. Food and Drug Administration (FDA). 15 June 2016. Retrieved 4 April 2020.


Allikas: https://en.wikipedia.org/wiki/Prezcobix
No tags for this post.